Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
Journal of the National Cancer Institute|October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Breast Cancer Research and Treatment|May 17, 2017
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A Yardley, Edward R Arrowsmith, Brooke R Daniel, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
ACS Nano|April 7, 2021
Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant EraÁngel Serrano-Aroca, Kazuo Takayama, Alberto Tuñón-Molina, et al.
Journal of the National Cancer Institute|July 3, 2018
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable TargetsDamir Varešlija, Nolan Priedigkeit, Ailís Fagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer StudyRoisin M Connolly, Huili Li, Rachel C Jankowitz, et al.
Nature Cancer|February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trialEvanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.
Pageof 21